Revenue was principally generated from agreements with Unilever in respect of the development of Hoodia extract, Schering-Plough in respect of sales of the veterinary product Phytopica and from the sale of raw materials from inventory.
Development costs fell to 3.91m from 4.25m, reflecting reduced expenditure on the Hoodia extract programmes following termination arrangements with Unilever, offset by the increase in expenditure incurred on Cogane studies.